Literature DB >> 20200516

Obesity, inflammation, and cardiovascular risk.

P Mathieu1, I Lemieux, J-P Després.   

Abstract

Obesity, a highly prevalent condition, is heterogeneous with regard to its impact on cardiovascular disease (CVD) risk. Epidemiological observations and metabolic investigations have consistently demonstrated that the accumulation of excess visceral fat is related to an increased risk of CVD as well as several metabolic and inflammatory perturbations. In the past decade, data from several studies have served to emphasize that atherosclerosis has an inflammatory component that may contribute to several key pathophysiological processes. Study data have also highlighted the finding that the expanded visceral fat is infiltrated by macrophages that conduct "cross-talk" with adipose tissue through several significant mechanisms. In this review, we provide, in the context of CVD risk, an up-to-date account of the complex interactions that occur between a dysfunctional adipose tissue phenotype and inflammation.

Entities:  

Mesh:

Year:  2010        PMID: 20200516     DOI: 10.1038/clpt.2009.311

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  130 in total

Review 1.  Heme oxygenase, a novel target for the treatment of hypertension and obesity?

Authors:  Peter A Hosick; David E Stec
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-11-09       Impact factor: 3.619

Review 2.  Designing phenotyping studies for genetically engineered mice.

Authors:  C J Zeiss; J M Ward; H G Allore
Journal:  Vet Pathol       Date:  2011-09-19       Impact factor: 2.221

3.  Is obesity a prognostic factor for acute myeloid leukemia outcome?

Authors:  Hun Ju Lee; Andrea S Licht; Andrew J Hyland; Laurie A Ford; Sheila N J Sait; Annemarie W Block; Maurice Barcos; Maria R Baer; Eunice S Wang; Meir Wetzler
Journal:  Ann Hematol       Date:  2011-09-21       Impact factor: 3.673

4.  Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients.

Authors:  Simone van Kralingen; Jeroen Diepstraten; Mariska Y M Peeters; Vera H M Deneer; Bert van Ramshorst; René J Wiezer; Eric P A van Dongen; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

5.  Adipose tissue-derived stem cells secrete CXCL5 cytokine with chemoattractant and angiogenic properties.

Authors:  Haiyang Zhang; Hongxiu Ning; Lia Banie; Guifang Wang; Guiting Lin; Tom F Lue; Ching-Shwun Lin
Journal:  Biochem Biophys Res Commun       Date:  2010-10-27       Impact factor: 3.575

6.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

7.  Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample.

Authors:  Mai Duong; Abdelilah Abouelfath; Regis Lassalle; Cécile Droz; Patrick Blin; Nicholas Moore
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

8.  Excess body mass is associated with T cell differentiation indicative of immune ageing in children.

Authors:  G Spielmann; C A Johnston; D P O'Connor; J P Foreyt; R J Simpson
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

9.  Inflammation is associated with the remodeling of calcific aortic valve disease.

Authors:  Nancy Coté; Ablajan Mahmut; Yohan Bosse; Christian Couture; Sylvain Pagé; Sylvain Trahan; Marie-Chloé Boulanger; Dominique Fournier; Philippe Pibarot; Patrick Mathieu
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

10.  The Role of Peroxisome Proliferator-Activated Receptor beta/delta on the Inflammatory Basis of Metabolic Disease.

Authors:  Teresa Coll; Emma Barroso; David Alvarez-Guardia; Lucía Serrano; Laia Salvadó; Manuel Merlos; Xavier Palomer; Manuel Vázquez-Carrera
Journal:  PPAR Res       Date:  2010-07-27       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.